LAMEA Neurological Biomarkers Market Size, Share & Industry Trends Analysis Report By Type (Proteomic, Genomic, Metabolomic), By Application (Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis), By Country and Growth Forecast, 2022 - 2028

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Neurological Biomarkers Market, by Type
1.4.2 LAMEA Neurological Biomarkers Market, by Application
1.4.3 LAMEA Neurological Biomarkers Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. LAMEA Neurological Biomarkers Market by Type
3.1 LAMEA Proteomic Market by Country
3.2 LAMEA Genomic Market by Country
3.3 LAMEA Metabolomic Market by Country
3.4 LAMEA Others Market by Country

Chapter 4. LAMEA Neurological Biomarkers Market by Application
4.1 LAMEA Alzheimer's Disease Market by Country
4.2 LAMEA Parkinson’s Disease Market by Country
4.3 LAMEA Multiple Sclerosis Market by Country

Chapter 5. LAMEA Neurological Biomarkers Market by Country
5.1 Brazil Neurological Biomarkers Market
5.1.1 Brazil Neurological Biomarkers Market by Type
5.1.2 Brazil Neurological Biomarkers Market by Application
5.2 Argentina Neurological Biomarkers Market
5.2.1 Argentina Neurological Biomarkers Market by Type
5.2.2 Argentina Neurological Biomarkers Market by Application
5.3 UAE Neurological Biomarkers Market
5.3.1 UAE Neurological Biomarkers Market by Type
5.3.2 UAE Neurological Biomarkers Market by Application
5.4 Saudi Arabia Neurological Biomarkers Market
5.4.1 Saudi Arabia Neurological Biomarkers Market by Type
5.4.2 Saudi Arabia Neurological Biomarkers Market by Application
5.5 South Africa Neurological Biomarkers Market
5.5.1 South Africa Neurological Biomarkers Market by Type
5.5.2 South Africa Neurological Biomarkers Market by Application
5.6 Nigeria Neurological Biomarkers Market
5.6.1 Nigeria Neurological Biomarkers Market by Type
5.6.2 Nigeria Neurological Biomarkers Market by Application
5.7 Rest of LAMEA Neurological Biomarkers Market
5.7.1 Rest of LAMEA Neurological Biomarkers Market by Type
5.7.2 Rest of LAMEA Neurological Biomarkers Market by Application

Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Bio-Rad laboratories, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expenses
6.3 Merck Group
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 PerkinElmer, Inc.
6.4.1 Company Overview
6.4.1 Financial Analysis
6.4.2 Segmental and Regional Analysis
6.4.3 Research & Development Expense
6.5 Shimadzu Corporation
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.6 Thermo Fisher Scientific, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 BioMérieux S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expenses
6.8 Myriad Genetics, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental Analysis
6.8.4 Research & Development Expenses
6.9 Quanterix Corporation
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.10. Neuro-Bio Ltd.
6.10.1 Company Overview